Literature DB >> 11433397

Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells.

R Hamasuna1, H Kataoka, J Y Meng, H Itoh, T Moriyama, S Wakisaka, M Koono.   

Abstract

Hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) is a serine proteinase inhibitor that contains 2 Kunitz-domains and a presumed transmembrane domain. It has broad inhibitory spectra against various serine proteinases showing potent inhibitory activities not only to hepatocyte growth factor activator but also to plasmin, trypsin and kallikreins. In this study, we investigated the expression of HAI-2/PB in human gliomas in vivo and the effects of HAI-2/PB on the fibrinolytic and invasive capabilities of human glioblastoma cells in vitro. With RNA blot analysis, HAI-2/PB mRNA was expressed in normal brain and in low-grade astrocytomas, but was hardly detectable in anaplastic astrocytomas and glioblastomas, indicating that its expression levels were inversely correlated with the histological grade of human gliomas. To further explore the possible role of HAI-2/PB in glioma progression, cultured human glioblastoma cell lines (U251 and YKG-1) were transiently transfected with an expression vector harboring human HAI-2/PB cDNA. Subsequent analysis indicated that the expression of HAI-2/PB suppressed the fibrinolytic activities of both glioblastoma cell lines. Moreover, HAI-2/PB inhibited Matrigel invasion of U251 and YKG-1 cells by 30% and 64%, respectively. This anti-invasive effect appeared to be mediated primarily by the inhibitory activity of HAI-2/PB against the serine proteinase-dependent matrix degradation. These findings suggest that the reduced expression of HAI-2/PB is possibly involved in the progression of human gliomas. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11433397     DOI: 10.1002/ijc.1349

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

Review 1.  The Inter-α-Trypsin Inhibitor Family: Versatile Molecules in Biology and Pathology.

Authors:  Megan S Lord; James Melrose; Anthony J Day; John M Whitelock
Journal:  J Histochem Cytochem       Date:  2020-07-08       Impact factor: 2.479

2.  Loss of SPINT2 expression frequently occurs in glioma, leading to increased growth and invasion via MMP2.

Authors:  Márcia Santos Pereira; Sónia Pires Celeiro; Ângela Margarida Costa; Filipe Pinto; Sergey Popov; Gisele Caravina de Almeida; Júlia Amorim; Manuel Melo Pires; Célia Pinheiro; José Manuel Lopes; Mrinalini Honavar; Paulo Costa; José Pimentel; Chris Jones; Rui Manuel Reis; Marta Viana-Pereira
Journal:  Cell Oncol (Dordr)       Date:  2019-11-07       Impact factor: 6.730

3.  SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.

Authors:  Fei Liu; Christopher D Cox; Reshmi Chowdhury; Laura Dovek; Huytram Nguyen; Tie Li; Sichen Li; Byram Ozer; Arthur Chou; Nhung Nguyen; Bowen Wei; Joseph Antonios; Horacio Soto; Harley Kornblum; Linda Liau; Robert Prins; P Leia Nghiemphu; William Yong; Timothy Cloughesy; Albert Lai
Journal:  J Neurooncol       Date:  2019-03-05       Impact factor: 4.130

4.  Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation.

Authors:  Phanindra K M Venukadasula; Benjamin Y Owusu; Namita Bansal; Larry J Ross; Judith V Hobrath; Donghui Bao; Jackie W Truss; Murray Stackhouse; Troy E Messick; Lidija Klampfer; Robert A Galemmo
Journal:  ACS Med Chem Lett       Date:  2015-12-22       Impact factor: 4.345

5.  Differential expression of bikunin (HAI-2/PB), a proposed mediator of glioma invasion, by demethylation treatment.

Authors:  James M Schuster; Maria Longo; Peter S Nelson
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

6.  Identification of Global DNA Methylation Signatures in Glioblastoma-Derived Cancer Stem Cells.

Authors:  Eun-Joon Lee; Prakash Rath; Jimei Liu; Dungsung Ryu; Lirong Pei; Satish K Noonepalle; Austin Y Shull; Qi Feng; N Scott Litofsky; Douglas C Miller; Douglas C Anthony; Mark D Kirk; John Laterra; Libin Deng; Hong-Bo Xin; Xinguo Wang; Jeong-Hyeon Choi; Huidong Shi
Journal:  J Genet Genomics       Date:  2015-06-24       Impact factor: 4.275

7.  SPINT2 Deregulation in Prostate Carcinoma.

Authors:  Márcia Santos Pereira; Gisele Caravina de Almeida; Filipe Pinto; Marta Viana-Pereira; Rui Manuel Reis
Journal:  J Histochem Cytochem       Date:  2015-10-06       Impact factor: 2.479

Review 8.  Mechanisms of hepatocyte growth factor activation in cancer tissues.

Authors:  Makiko Kawaguchi; Hiroaki Kataoka
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

9.  Hepatocyte growth factor activator inhibitor-1 is induced by bone morphogenetic proteins and regulates proliferation and cell fate of neural progenitor cells.

Authors:  Raili Koivuniemi; Johanna Mäkelä; Marie-Estelle Hokkanen; Céline Bruelle; Tho Huu Ho; Roxana Ola; Laura Korhonen; Jim Schröder; Hiroaki Kataoka; Dan Lindholm
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

10.  Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.

Authors:  Benjamin Y Owusu; Namita Bansal; Phanindra K M Venukadasula; Larry J Ross; Troy E Messick; Sanjay Goel; Robert A Galemmo; Lidija Klampfer
Journal:  Oncotarget       Date:  2016-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.